数字应用改善高危CKD门诊患者用药安全:随机对照试验
该随机对照试验纳入182例晚期CKD门诊患者,比较eKidneyCare(含每月用药审查提醒并与临床医生对账)与MyMedRec(独立存储用药信息应用)对用药差异的影响。1年后eKidneyCare组用药差异率及严重程度显著低于MyMedRec组,且每月完成至少一次用药审查的患者比例更高。
要点
- eKidneyCare较MyMedRec显著降低CKD患者用药差异率(中位0.45 vs 0.67,P=0.001)。
- eKidneyCare降低临床相关用药差异严重程度,潜在严重危害差异率比0.40(95%CI 0.27-0.63)。
- eKidneyCare组72%患者每月至少完成一次用药审查,MyMedRec组仅30%保留用药档案。
核心结论
- 在高危CKD门诊患者中,eKidneyCare较MyMedRec显著降低用药差异的发生率和严重程度,而用药差异是用药错误的近端原因。
研究设计与样本
- 1年随机对照试验,纳入182例晚期CKD门诊患者,随机分配至eKidneyCare组(n=89)或MyMedRec组(n=93)。
主要发现
- 退出时eKidneyCare组总用药差异中位0.45(IQR 0.33-0.63),MyMedRec组0.67(IQR 0.40-1.00),P=0.001。
- eKidneyCare组基线变化0.13±0.27,MyMedRec组0.30±0.41,P=0.007。
- eKidneyCare降低所有类别临床相关用药差异的严重程度,包括潜在严重危害差异(估计率比0.40,95%CI 0.27-0.63)。
- eKidneyCare组72%患者每月至少完成一次用药审查,MyMedRec组仅30%(经脱落校正)在手机上保留用药档案。
临床怎么用
- eKidneyCare类数字工具可整合于CKD门诊用药安全管理,通过每月审查和医患对账早期发现并干预用药差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients with CKD are at risk for adverse drug reactions, but effective community-based preventive programs remain elusive. In this study, we compared the effectiveness of two digital applications designed to improve outpatient medication safety. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a 1-year randomized controlled trial, 182 outpatients with advanced CKD were randomly assigned to receive a smartphone preloaded with either eKidneyCare (n=89) or MyMedRec (n=93). The experimental intervention, eKidneyCare, includes a medication feature that prompted patients to review medications monthly and report changes, additions, or medication problems to clinicians for reconciliation and early intervention. The active comparator was MyMedRec, a commercially available, standalone application for storing medication and other health information that can be shared with patients' providers. The primary outcome was the rate of medication discrepancy, defined as differences between the patient's reported history and the clinic's medication record, at exit. RESULTS: At exit, the eKidneyCare group had fewer total medication discrepancies compared with MyMedRec (median, 0.45; interquartile range, 0.33-0.63 versus 0.67; interquartile range, 0.40-1.00; P=0.001), and the change from baseline was 0.13±0.27 in eKidneyCare and 0.30±0.41 in MyMedRec (P=0.007). eKidneyCare use also reduced the severity of clinically relevant medication discrepancies in all categories, including those with the potential to cause serious harm (estimated rate ratio, 0.40; 95% confidence interval, 0.27 to 0.63). Usage data revealed that 72% of patients randomized to eKidneyCare completed one or more medication reviews per month, whereas only 30% of patients in the MyMedRec group (adjusted for dropouts) kept their medication profile on their phone. CONCLUSIONS: In patients who are high risk and have CKD, eKidneyCare significantly reduced the rate and severity of medication discrepancies, the proximal cause of medication errors, compared with the active comparator. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: www.ClinicalTrials.gov, NCT:02905474.
引用
- Ong SW, Jassal SV, Porter EC, et al. Digital Applications Targeting Medication Safety in Ambulatory High-Risk CKD Patients: Randomized Controlled Clinical Trial. Clin J Am Soc Nephrol. 2021. PMID: 33737321. doi:10.2215/CJN.15020920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。